Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley Sells 10,000 Shares

Exelixis, Inc. (NASDAQ:EXEL) EVP Patrick J. Haley sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $42.68, for a total value of $426,800.00. Following the transaction, the executive vice president now owns 491,164 shares in the company, valued at approximately $20,962,879.52. This trade represents a 2.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Exelixis Stock Down 1.9%

EXEL stock opened at $45.40 on Friday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $48.85. The company has a market cap of $12.51 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. The business’s 50-day simple moving average is $37.23 and its 200 day simple moving average is $35.82.

Analyst Ratings Changes

A number of brokerages recently weighed in on EXEL. Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a research note on Thursday, April 17th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Exelixis in a report on Thursday, March 27th. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Finally, Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $38.76.

Institutional Trading of Exelixis

Hedge funds have recently modified their holdings of the company. Frank Rimerman Advisors LLC raised its stake in shares of Exelixis by 4.7% in the first quarter. Frank Rimerman Advisors LLC now owns 6,342 shares of the biotechnology company’s stock valued at $234,000 after purchasing an additional 285 shares in the last quarter. MassMutual Private Wealth & Trust FSB increased its holdings in Exelixis by 18.1% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 290 shares during the period. Farther Finance Advisors LLC increased its holdings in Exelixis by 6.1% in the 1st quarter. Farther Finance Advisors LLC now owns 5,372 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 307 shares during the period. Balyasny Asset Management L.P. raised its stake in shares of Exelixis by 1.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock valued at $573,000 after buying an additional 317 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC lifted its holdings in shares of Exelixis by 4.9% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 330 shares during the period. Institutional investors own 85.27% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.